Evidence map›Paper›PMID 40141193›Full record

ArticleInternational journal of molecular sciences2025

Evaluation of the Inhibitory Potential of Apigenin and Related Flavonoids on Various Proteins Associated with Human Diseases Using AutoDock.

Tanat Peanlikhit, Uma Aryal, James S Welsh, Kenneth R Shroyer, Kanokporn Noy Rithidech

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tanat PeanlikhitPathology Department, Stony Brook University, Stony Brook, NY 11794-8691, USA.ORCID 0000-0002-8334-1980
Uma AryalDepartment of Comparative Pathobiology, Purdue University, West Lafayette, IN 47907, USA.ORCID 0000-0003-4543-1536
James S WelshDepartment of Radiation Oncology, Loyola University Health System, Maywood, IL 60153, USA.ORCID 0000-0002-3255-6412
Kenneth R ShroyerPathology Department, Stony Brook University, Stony Brook, NY 11794-8691, USA.ORCID 0000-0001-8090-0778
Kanokporn Noy RithidechPathology Department, Stony Brook University, Stony Brook, NY 11794-8691, USA.ORCID 0000-0002-7153-091X

Funding

NASA #80NSSC19K04325
6 · The paper itself

Abstract

We used molecular docking to determine the binding energy and interactions of apigenin and 16 related flavonoids, with 24 distinct proteins having diverse biological functions. We aimed to identify potential inhibitors of these proteins and understand the structural configurations of flavonoids impacting their binding energy. Our results demonstrate that apigenin exhibits high binding energies (a surrogate for binding affinity or inhibitory potential) to all tested proteins. The strongest binding energy was -8.21 kcal/mol for p38 mitogen-activated protein kinases, while the weakest was -5.34 kcal/mol for cyclin-dependent kinase 4. Apigenin and many other flavonoids showed high binding energies on xanthine oxidase (1.1-1.5 fold of febuxostat) and DNA methyltransferases (1.1-1.2 fold of azacytidine). We uncovered high binding energies of apigenin and certain flavonoids with mutated Kirsten rat sarcoma viral oncogene homolog at G12D (KRAS G12D), G12V, and G12C. Consequently, apigenin and certain flavonoids have the potential to effectively inhibit pan-KRAS oncogenic activity, not just on specific KRAS mutations. Apigenin and certain flavonoids also have high binding energies with aromatase (involved in estrogen production) and bacterial infections, i.e., DNA gyrase B and 3R-hydroxy acyl-ACP dehydratase (FABZ). Our findings are pivotal in identifying specific flavonoids that can effectively inhibit targeted proteins, paving the way for the development of innovative flavonoid-based drugs.

Indexed as

ApigeninFlavonoidsMolecular Docking SimulationHumansProtein BindingProto-Oncogene Proteins p21(ras)Xanthine OxidaseApigeninFlavonoidsProto-Oncogene Proteins p21(ras)Xanthine Oxidaseapigeninbacterial infectionsflavonoidsKRAS mutationsmolecular dockingoxidative stress and inflammation

Identifiers

PMID40141193
PMCPMC11942390

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.